NCT04648189 2023-10-19
Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC
The Netherlands Cancer Institute
Phase 2 Withdrawn
The Netherlands Cancer Institute
NKGen Biotech, Inc.
Eli Lilly and Company
UNC Lineberger Comprehensive Cancer Center